Vaccine

First Coronavirus Vaccine Tested in Humans Shows Early Promise

The vaccine, developed by government scientists and Moderna, a biotech company, appeared safe and provoked an immune response in 45 people in a study.
An experimental coronavirus vaccine made by the biotech company Moderna provoked a promising immune response against the virus and appeared safe in the first 45 people who received it, researchers reported on Tuesday in The New England Journal of Medicine.

Moderna’s vaccine, developed with researchers at the National Institute of Allergy and Infectious Diseases, was the first coronavirus vaccine to be tested in humans, and the company announced on Tuesday that large Phase 3 tests of it would begin on July 27, involving 30,000 people. Half of the participants will be a control group who will receive placebos.

This large clinical trial is expected to be completed by late October. But it’s not clear whether it will be possible to prove the vaccine is safe and effective by then. The trial will need to show that those who were vaccinated were significantly less likely to contract the virus than those who got a placebo. The fastest way to get results is to test the vaccine in a “hot spot” with many cases, and the study is looking for people at high risk because of their locations or circumstances.

Vaccines and improved treatments are the only hope of returning lives back to anything close to normal, and dozens of companies are racing to develop vaccines. Experts agree that more than one vaccine will be needed, because no single company could produce the billions of doses needed.